PrognosDx, Accium Partner to Develop Histone-based Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PrognosDx Health today announced a deal with Accium BioScience to develop and commercialize tests based on histone biomarkers.

Palo Alto, Calif.-based PrognosDx will lend its expertise and epigenetic platform technology to the partnership, while Accium, headquartered in Seattle, will contribute its accelerator mass spectrometry platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.